Navigation Links
Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
Date:12/8/2009

'_blank' title='http://www.CellTherapeutics.com/investors_alert'>http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the securities of CTI. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma as determined by the U.S. Food and Drug Administration, the potential failure of pixantrone to significantly reduce cardiac cell toxicity compared to currently marketed anthracyclines, the potential failure of pixantrone to reintroduce an effective anthracycline like agent in patients, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.


Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:
Ed Bell
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BD Ranked in the Top 100 Greenest Big Companies by Newsweek; Named Again to Dow Jones Sustainability World and North America Indexes
2. US Oncology, Inc. to Exhibit iKnowMed(TM) at the 2009 ASCO EHR Symposium: Harnessing the EHR: From Incentives to Sustainability
3. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
4. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
5. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
6. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
7. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
8. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
9. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
10. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
11. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... YORK , Sept. 17, 2014 ... Summary GlobalData,s new report, "Germany Gynecological ... data on the Germany Gynecological Devices market. The ... volume (in units) and average prices (in US ... (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization Devices ...
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 ... of PDL BioPharma, Inc. ("PDL BioPharma" or the "Company") ... Robert S. Willoughby at rswilloughby@pomlaw.com or ... PDL BioPharma and certain of its officers and/or directors ... Exchange Act of 1934.  On September ...
(Date:9/17/2014)... Sept. 17, 2014 Bronstein, Gewirtz & Grossman, ... of the securities of PDL BioPharma, Inc. ("PDL BioPharma" ... Such investors are advised to contact Peretz Bronstein ... at info@bgandg.com or 212-697-6484. ... of its executives violated federal securities laws. ...
Breaking Medicine Technology:Germany Gynecological Devices Market Outlook to 2020 2Germany Gynecological Devices Market Outlook to 2020 3SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
... Annual Review of the Pharmaceutical Industry and the issues it ... Analyst Christopher Bowe. Bowe,s articles top issues faced by the ... Management" – an examination of how companies will use lifecycle ... corporate value , "Stamp Your Mark and Lead" – ...
... Edwards, Inc. (Nasdaq: MSHL ), an oncology ... targeting cancer metabolism, announced today that it has filed ... and Exchange Commission for a rights offering to existing ... common stock. The Company will announce further details regarding ...
Cached Medicine Technology:Need for Pharma Industry Change, Effective Lifecycle Management and Corporate Brand Reputation Featured in Scrip 100 2Marshall Edwards Announces Rights Offering to Stockholders 2Marshall Edwards Announces Rights Offering to Stockholders 3
(Date:9/18/2014)... 18, 2014 INDIGO Biosciences, a leading ... that it has released a new Human Estrogen-related Orphan ... kits are available. , ERR? is naturally expressed in ... in a variety of other tissue types, including kidney, ... a potential target for anti-obesity therapeutics. Cross-talk between ...
(Date:9/18/2014)... September 18, 2014 Sutter Health’s California ... founder of Dolby Laboratories, by naming the Ray Dolby ... of Ray Dolby provided a founding gift of $21 ... which provides services to patients and families suffering from ... people have been treated at the center since its ...
(Date:9/18/2014)... September 18, 2014 Dentists from ... of highly acclaimed Oxnard All-on-4™ dental implants ... a prosthodontist from the Anacapa Dental Art Institute ... the Canadian Academy of Restorative Dentistry and Prosthodontics ... Reshad’s presentation, “Resection Versus Augmentation: Esthetic Implant Supported ...
(Date:9/18/2014)... 2014 Each year, Norman Regional Hospital ... coincide with National Health IT (NHIT) Week to celebrate ... help Norman Regional show its gratitude, Access, the ... is contributing giveaway items to support their NHIT Week ... and offering free lunches, Norman Regional is spending time ...
(Date:9/18/2014)... Fla (PRWEB) September 18, 2014 According to ... suffer from eczema, with many of them being children. In ... first diagnosed as babies and children. The millions of children ... can be brought on by eczema. A new book has ... who they are and to find relief from the condition ...
Breaking Medicine News(10 mins):Health News:INDIGO Offers Human Estrogen-related Receptor Gamma Assay System 2Health News:Sutter Health’s CPMC announces Ray Dolby Brain Health Center 2Health News:Sutter Health’s CPMC announces Ray Dolby Brain Health Center 3Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 2Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 3Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 4Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 5Health News:Access Helps Norman Regional Hospital Celebrate Its Staff During National Health IT Week 2014 2Health News:New Book Helps Millions of Children Deal With The Emotional Pains of Suffering From Eczema 2
... these conditions go untreated , , MONDAY, May 12 (HealthDay News) ... are bad for your heart, they may also harm your ... to increase one,s risk for retinal vein occlusion, a condition ... more veins carrying blood from the eye to the heart ...
... PITTSBURGH Carnegie Mellon Universitys Justin Y. Newberg and Robert F. Murphy have ... protein patterns in human tissues., ... student in biomedical engineering, described the automated protein pattern recognition tool and ... for cancer diagnosis and therapy. , ...
... Damir Matic, a scientist with Lawson Health Research Institute in ... performed throughout North America and around the world. Matic ... close the gum tissue of cleft palate patients. His research ... is older. , Matic is a craniofacial/plastic surgeon at London ...
... U.S. survey estimates 750,000, mostly males, are hooked , , ... American teens and young adults are problem gamblers according ... on Addictions. , Problem gambling is defined as ... as gambling more than you intended or stealing money ...
... OmniSonics Medical,Technologies, Inc., a developer of advanced medical ... announced today that it has enrolled its,first patient ... a prospective,multi-center U.S. registry study of the company,s ... thrombectomy,for acute limb ischemia (ALI). All patients enrolled ...
... BETHESDA, Md., May 12 Naturlose, a natural sugar,approved as ... found to,reduce the spikes of serum glucose that follow consumption ... (Nasdaq: SPEX ) is currently,studying the efficacy and safety ... trial is ongoing, Spherix has engaged market,research companies to seek ...
Cached Medicine News:Health News:High Blood Pressure, Cholesterol Associated With Eye Disease 2Health News:Carnegie Mellon engineering researchers automate analysis of protein patterns 2Health News:Research shows timing improves cleft palate surgery 2Health News:Problem Gambling Common Among Young Adults 2Health News:OmniSonics Medical Technologies Announces First Patient Enrolled in SONIC II REGISTRY 2Health News:Market Research Shows Spherix's Naturlose(R) Readily Accepted by Diabetes Patients 2Health News:Market Research Shows Spherix's Naturlose(R) Readily Accepted by Diabetes Patients 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: